Reading Room Production — page 458

From: "Emanuel, Ezekiel (NIH/CC/BEP) (E]" RY @cc.nih.gov> To: "Lurie, Nicole (0S)" EE @ hs. gov> Ce: "Hatchett, Richard J." REE © who.cop.gov>, "Merchant, Raina (HHS/ASPR)" @hhs.gov>, "Robinson, Robin (OS)" I! @HHS.GOV>, "Fauci, Anthony (NIH/NIAID) [E]" <AFAUCI@niaid.nih.gov>, "Borio, Luciana L (FDA)" @fda.hhs.gov>, "Avery, Heidi E." EEE © 0.cop.gov>, "Korch, George (OS)" @hhs.gov> Subject: RE: Synopsis of Conversation with Pharma/Bio Reps 29 Jan 2010 Date: Mon, 01 Feb 2010 08:49:47 -0500 Importance: Normal Iam not taking it off the table only think it is very limited. If we want to solve the problem we should not think small pieces will work. Furthermore, things that require some govt official to make a determination always count for less among private companies because they cannot be sure the govt official will rule the right way and in a timely manner. If we want the private sector to have confidence to allocate tens if not hundreds of millions then we need to give them some strong assurances and this does not seem to me to do it. Ezekiel J. Emanuel, M.D., Ph.D. Department of Bioethics The Clinical Center National Institutes of Health and Office of Management and Budget Executive Office of the President Phone Fax NIH OMB Cell Private -----Original Message----- From: Lurie, Nicole (OS) Sent: Sunday, January 31, 2010 9:37 PM To: Emanuel, Ezekiel (NIH/CC/BEP) [E] Cc: Hatchett, Richard J.; Merchant, Raina (HHS/ASPR); Robinson, Robin (OS); Fauci, Anthony (NIH/NIAID) [E]: Borio, Luciana L (FDA); Avery, Heidi E.; Korch, George (OS) Subject: RE: Synopsis of Conversation with Pharma/Bio Reps 29 Jan 2010 Out of curiosity, why would you take PRV off the table as a part of a package of incentives--agree that it cant work alone--n Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness and Response Rear Admiral, US Public Health Service Department of Health and Human Services 'Washington, DC